fda drug shortage semaglutide US judge upholds FDA's removal of Ozempic, Wegovy from list On February 21, 2025, the

[DOI] [PMC free article] [PubMed] [Google Scholar] Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M

Now its your turn: Are you using Wellbutrin

[9] Chronic dehydration or low fluid intake : Baseline inadequate hydration significantly increases stone risk, particularly when compounded by medication-induced fluid losses

Wall Street appeared to favor Lilly's expanding clinical pipeline over Novo's commercial momentum, highlighting the growing competition between the two pharmaceutical giants that dominate the GLP-1 obesity market

For manufacturers, the focus is less about choosing between formats, and more about building platforms that can scale intelligently, adapt to future modalities, and remain compliant under increasing regulatory scrutiny

The comparison between GLP-1 RAs and traditional antidepressants isn't always straightforward